Taro Pharmaceuticals (NYSE:TARO) is an Israeli-based pharmaceutical company that develops, manufactures, and markets nearly 200 prescription and OTC pharmaceutical products in the US (88% of sales), Canada (8% of sales), and Israel (3% of sales). Although Taro is finally drawing attention in the financial media with its 20%+ move up last week (driven by a Credit Suisse note), the company still flies under the radar and is largely unknown and underfollowed by Wall Street. Taro's impressive record of earnings growth and share price appreciation has largely gone unnoticed. Taro's continued execution combined with the lack of coverage provides room for 50%+ share price appreciation in the coming months as the story unfolds. This upside opportunity is driven by...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|